DeCode IDs tablet problem, suspends pivotal trial

Iceland's deCode Genetics [1] has suspended a late-stage trial of the heart attack prevention drug veliflapon after determining that the tablets being used weren't dissolving properly. Researchers were concerned that the faulty tablets would have skewed the data on the drug. The developer announced that it had notified the FDA and was looking at alternative manufacturing sources to resolve the issue. Veliflapon is directed at two genes which contain proteins linked to an elevated risk of heart attack. Another compound with a similar target is in early trials.

- read the report [2] on deCode from Hemscott